Intervention

Utidelone

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 7 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials7
Recruiting3
Common conditions9
Lead sponsors shown6
Advertisement

Clinical trials

7 shown
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain MetastasesNCT06764940 · 2025-07-14
RECRUITING
Organoid-based Functional Precision Therapy for Advanced Breast CancerNCT06102824 · 2024-10-01
RECRUITING
The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical StudyNCT06125080 · 2023-10-30
RECRUITING
Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain MetastasesNCT06683703 · 2024-12-01
NOT_YET_RECRUITING
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast CancerNCT05983094 · 2023-09-01
NOT_YET_RECRUITING
Utidelone in Third-line and Above Treatment of Small Cell Lung CancerNCT05299255 · 2021-09-05
UNKNOWN
PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast CancerNCT05052437 · 2020-10-15
COMPLETED

Trial status mix

RECRUITING3
NOT_YET_RECRUITING2
COMPLETED1
UNKNOWN1

Phase mix

PHASE26
PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.